The Beat Eliminating Data Waste: How Amgen’s Leandro Boer Is Reimagining Precision Medicine and Patient Equity
About Leandro Boer:
Leandro Boer, MD, PhD, is a seasoned global biopharmaceutical executive and physician specializing in cardiology and cardiovascular pharmacology. Currently serving as Vice President of US Medical, General Medicines at Amgen, he leads medical strategy and execution across cardiovascular, bone, neuroscience, nephrology, and obesity therapeutic areas, overseeing a nationwide organization of over 100 professionals. With more than two decades of experience spanning the United States, Latin America, Canada, Africa, and the Middle East, Dr. Boer has built a distinguished career at leading companies such as Amgen, AstraZeneca, and Novartis.
His leadership has shaped global and regional initiatives in medical affairs, clinical development, real-world evidence generation, regulatory strategy, and implementation science. Clinically, his expertise covers resistant hypertension, type 2 diabetes, obesity, heart failure, chronic kidney disease, and hyperlipidemia. Known for combining scientific rigor with strategic vision, Dr. Boer has directed cross-functional teams supporting drug development, commercialization, and lifecycle management across multiple therapeutic areas.
A medical doctor trained in cardiology with a Ph.D. in cardiovascular pharmacology from Universidade Estadual de Campinas, Dr. Boer has consistently demonstrated a commitment to advancing evidence-based medicine, patient outcomes, and collaborative leadership within the healthcare ecosystem.
Things You’ll Learn:
- The foundation of innovation lies in focusing on what never changes—patients, healthcare providers, and equitable systems of care.
- Amgen’s precision medicine and data-driven strategies prevent “data waste” and ensure every insight contributes to patient outcomes.
- Machine learning tools like Atomic are accelerating clinical trials by predicting successful sites, leading to faster drug development.
- The company’s bold goal to reduce cardiovascular events by 50% by 2030 relies on partnerships, AI, and implementation science.
- Representation in clinical research and decentralized trials is crucial to ensuring equitable access and meaningful outcomes for all populations.
Resources: